LA MIRADA, CA--(Marketwire - August 06, 2012) - BioLargo, Inc. (OTCBB: BLGO) announced today that former Smith & Nephew Vice President of Innovation (and Vice President at Smith & Nephew Wound Management) Tanya Rhodes has joined the BioLargo management team as a senior strategy advisor. Rhodes will work closely with BioLargo and its recently formed medical subsidiary to commercialize its technology in the wound management and medical device markets.
"I believe that the BioLargo technology presents a unique and cost-effective solution for a number of big problems facing the industry," stated Rhodes. "I look forward to working closely with the BioLargo team to help serve this important industry."
Having spent 15 years at Smith & Nephew U.S. and more than 20 years in the wound management and skin care industry globally, Rhodes has established a broad base of expertise that includes a concept-to-commercialization philosophy utilizing product design, strategic marketing and evidence-based trials as well as reimbursement and regulatory compliance strategies. Over her career, she played an instrumental role in bringing a number of staple wound care technologies to market around the globe. She holds a Masters Degree in Technology Management from the University of Miami and graduated with honors in Chemistry from Hull University, England. She also completed the full research for PhD in Molecular Orbital Computational Stereochemistry before relocating to the US.
"Tanya has more than 20 years of experience within the highly specialized wound management industry. She is a patent holder and has been intimate in the creation and design of patented and commercially successful wound care technologies across the globe. She brings a wealth of knowledge and experience to BioLargo," stated Dennis P. Calvert, President & CEO. "Our recent technical advancements for wound management applications are opening up major commercial market opportunities for BioLargo. With Tanya's leadership, we can move swiftly and wisely to capitalize on and manage the significant opportunities ahead."
About BioLargo, Inc.
BioLargo's business strategy is to harness and deliver Nature's Best Solution® -- free-iodine -- in a safe, efficient, environmentally sensitive and cost-effective manner. Its proprietary technology works by combining micro-nutrient salts with liquid from any source to deliver free-iodine on demand, in controlled dosages, in order to balance efficacy of performance with concerns about toxicity. The technology has potential commercial applications within global industries, including but not limited to oil and gas, animal health, beach and soil environmental uses, consumer products, agriculture, food processing, medical, and water. It features solutions for odor & moisture control, disinfection and contaminated water treatment. The company's goal is to improve the quality of life for people worldwide, while it protects the environment, and produces positive economic results for our customers, partners, and shareholders. Its website is www.BioLargo.com. Its Odor-No-More® product was awarded two Editor's Choice Awards, including a "Product of the Year" award, by the Horse Journal, a top industry publication, as well as a Best New Product SuperZoo Award, and are sold by BioLargo's wholly owned subsidiary, Odor-No-More, Inc. (www.OdorNoMore.com). BioLargo® also owns a 50% interest in the Isan System, already commercialized in Australia, which was honored with a Top 50 Water Company for the 21st Century award by the Artemis Project. In early 2011, the company signed an exclusive license agreement for use in pet products with industry leader Central Garden and Pet.
Safe Harbor Statement
The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo's current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo's Annual Report on Form 10-K for the year ended December 31, 2011.